Oncotarget

Research Papers:

Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells

Liping Han, Qingwei Zhao, Xianhong Liang, Xiaoqing Wang, Zhen Zhang, Zhiguo Ma, Miaoqing Zhao, Aihua Wang and Shuai Liu _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:45643-45655. https://doi.org/10.18632/oncotarget.17314

Metrics: PDF 776 views  |   HTML 1486 views  |   ?  


Abstract

Liping Han1,2,3,*, Qingwei Zhao3,*, Xianhong Liang3, Xiaoqing Wang4, Zhen Zhang5, Zhiguo Ma3, Miaoqing Zhao6, Aihua Wang2 and Shuai Liu1

1Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China

2Department of Neurology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China

3Department of Neurology, Shandong Police Hospital, Jinan, Shandong, P.R. China

4Department of Pediatric Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China

5Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China

6Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R China

*These authors have contributed equally to this work

Correspondence to:

Shuai Liu, email: 15866600623@163.com

Keywords: glioma, BRD4 inhibition, autophagy, HEXIM1, Akt pathway

Received: March 01, 2017    Accepted: April 03, 2017    Published: April 21, 2017

ABSTRACT

Inhibition of Brd4 by JQ1 treatment showed potential in the treatment of glioma, however, some cases showed low sensitivity of JQ1. In addition, the pre-clinical analysis showed its limitation by demonstrating that transient treatment with JQ1 leads to aggressive tumor development. Thus, an improved understanding of the mechanisms underlying JQ1 is urgently required to design strategies to improve its efficiency, as well as overcome its limitation. HEXIM1 has been confirmed to have an important role in regulating JQ1 sensitivity. In our study, ubenimex, a classical anti-cancer drug showed potential in regulating the JQ1 sensitivity of glioma cells using the WST-1 proliferation assay. Further studies demonstrated that ubenimex inhibited autophagy and downregulated the autophagic degradation of HEXIM1. The role of HEXIM1 in regulating JQ1 sensitivity was verified by the HEXIM1 knockdown. Since ubenimex was verified as an Akt inhibitor, we further studied the role of Akt inhibition in regulating JQ1 sensitivity and migration of glioma cells. Data showed that ubenimex improved the efficiency of JQ1 treatment and suppressed migration both in the in vitro and in vivo xenografts models. The Akt agonist attenuated these effects, pointing to the role of Akt inhibition in JQ1 sensitivity and suppressed migration. Our findings suggest the potential of ubenimex adjuvant treatment to enhance JQ1 efficiency and attenuate parts of its side effect (enhancing tumor aggressive) by regulating the autophagic degradation of HEXIM1 and Akt inhibition.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17314